查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1494911

體外診斷 (IVD) 市場至2030年的預測：按產品、檢體、技術、應用、最終用戶和地區的全球分析

In Vitro Diagnostics (IVD) Market Forecasts to 2030 - Global Analysis By Product (Instruments, Reagents & Kits and Software), Specimen (Blood, Urine, Stool, Saliva, Tissue Biopsies and Other Specimens), Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據Stratistics MRC的資料，2024年全球體外診斷（IVD）市場規模為1,041億美元，預計到2030年將達到1,485億美元，預測期內年複合成長率為6.1%。

體外診斷（IVD）是對從人體採集的樣本（例如血液、尿液或組織）進行的醫學測試，以檢測疾病、狀況或感染疾病。這些測試在體外、受控的實驗室環境中進行，在現代醫療保健和個人化醫療中發揮重要作用，為診斷、治療監測和疾病預防提供關鍵資訊。

根據美國生物技術資訊中心（NCBI）的報告，體外診斷（IVD）測試在臨床實踐中很有價值，88%的患者用於初步診斷，77%用於治療監測，72%的患者用於治療用於治療後續觀察。這凸顯了 IVD 在病患管理和醫療保健中的重要角色。

慢性病增加

糖尿病、心血管疾病和癌症等慢性疾病的上升趨勢是體外診斷（IVD）市場的關鍵促進因素。這些疾病需要定期監測和早期診斷，體外診斷（IVD）測試有助於實現這一目標。隨著世界人口老化以及與生活方式相關的健康問題的增加，對準確、高效的診斷工具的需求不斷增加，推動了市場的擴張。

診斷平台高成本

先進診斷平台的高成本是體外診斷市場的主要限制因素。這些平台通常需要大量投資，包括初始設置、維護和熟練人員。較小的醫療機構和新興市場可能會發現難以承擔實施這些技術的成本，限制了採用並可能減緩市場成長。此外，成本因素可能會阻礙新技術的頻繁升級和整合。

新興市場的成長

新興市場代表了 IVD 市場的主要成長機會。亞太、拉丁美洲和非洲部分地區等地區經濟快速發展，衛生基礎建設不斷改善，衛生支出不斷增加。這些因素，加上人們對早期疾病檢測和預防保健意識的增強，為體外診斷（IVD）產品和服務的擴展提供了肥沃的土壤。在這些地區投資的公司可以開拓到許多服務不足的患者。

嚴格的法律規範

管理體外診斷的核准和商業化的嚴格法律規範是市場成長的主要威脅。 FDA 和 EMA 等監管機構制定了嚴格的標準，以確保診斷測試的安全性和有效性。這些法規雖然保護病人安全，但也延長了核准流程並增加了製造商的成本。違規可能導致產品召回、法律問題和市場信心喪失。

COVID-19 的影響：

COVID-19 大流行大幅推動了 IVD 市場的發展，對 PCR、NGS 和基於血清學的快速檢測等診斷檢測的需求激增。這次疫情加速了就地檢驗和遠距離診斷的採用，凸顯了快速、準確的診斷解決方案的重要性。需求激增導致對 IVD 技術和基礎設施的投資增加，為未來的成長開創了先例。

試劑和套件細分市場預計將成為預測期內最大的細分市場

試劑和套件領域預計將主導 IVD 市場，因為它在診斷測試中發揮重要作用。試劑是各種體外診斷測試中用於檢測和測量患者樣本中特定分析物的關鍵組件。常規診斷程序對這些消耗品的持續需求，加上試劑配方的進步和新檢測套組的推出，推動該領域的成長。

免疫測量領域預計在預測期內年複合成長率最高

免疫測量領域由於其廣泛的應用，包括感染疾病、癌症生物標記和荷爾蒙濃度的檢測，預計將出現最高的年複合成長率。免疫檢測具有較高的敏感性和特異性，對於臨床診斷非常重要。自動免疫檢測系統等技術進步和多重分析的市場開拓進一步提高了其效率和採用率，促進了市場的快速成長。

佔有率最大的地區

北美由於其先進的醫療基礎設施、高昂的醫療成本以及主要 IVD 公司的存在，在 IVD 市場佔據主導地位。該地區對早期疾病檢測、個人化醫療和先進診斷技術引進的關注推動市場成長。此外，政府的支持政策和慢性病的高盛行率也促進了北美的主要市場佔有率。

年複合成長率最高的地區：

由於醫療保健投資增加、醫療保健基礎設施改善以及預防醫學意識不斷增強，預計亞太地區 IVD 市場將快速成長。慢性病和感染疾病患者的上升，經濟的發展和中產階級的壯大推動對先進診斷解決方案的需求。政府為改善醫療保健的可近性和可負擔性所做的努力進一步支持了該地區的高年複合成長率。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多3家公司）
    • 主要企業SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 技術分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球體外診斷（IVD）市場：依產品

  • 裝置
    • 分析儀
    • 照護現場（POC）設備
    • 顯微鏡
    • 其他儀器
  • 試劑和套件
    • 分子診斷試劑套件
    • 臨床化學測試
    • 血液學檢查
    • 微生物學檢測
    • 其他試劑和套件
  • 軟體
    • 資料分析軟體
    • 實驗室資訊管理系統（LIMS）
    • 遠端診斷軟體

第6章 全球體外診斷（IVD）市場：檢體

  • 血
  • 尿
  • 糞便
  • 唾液
  • 切片檢查
  • 其他標本

第7章 全球體外診斷（IVD）市場：依技術分類

  • 免疫學測試
    • 酵素免疫分析法測定法（ELISA）
    • 化學冷光免疫檢測（CLIA）
    • 免疫檢測（RIA）
  • 分子診斷
    • 聚合酵素鏈鎖反應（PCR）
    • 恒溫核酸增幅技術（INAAT）
    • 微陣列
    • 次世代定序（NGS）
  • 臨床化學
  • 血液學
  • 微生物學
  • 凝血和止血
  • 其他技術

第8章 全球體外診斷（IVD）市場：依應用分類

  • 感染疾病
    • 愛滋病毒/愛滋病檢測
    • 肝炎測試
    • 細菌和病毒感染
  • 腫瘤學
    • 癌症篩檢和診斷
    • 監測治療反應
  • 內分泌學
    • 糖尿病測試
    • 甲狀腺功能檢查
  • 心臟病學
    • 心臟標記測試
    • 膽固醇測試
  • 驗血
    • 新生兒篩檢
    • 產前檢測
  • 基因檢測
    • 職業篩檢
    • 藥物基因組學
  • 自體免疫疾病
    • 類風濕性關節炎測試
    • 乳糜瀉測試
  • 過敏診斷
    • 食物過敏測試
    • 藥物過敏測試
  • 藥物監測和檢測
    • 治療藥物監測
    • 反興奮劑測試
  • 血液凝固檢驗
    • 血型分類
    • 骨骼和礦物質疾病
  • 其他用途

第9章 全球體外診斷（IVD）市場：依最終用戶分類

  • 醫院/診所
  • 診斷實驗室
  • 就地檢驗設施
  • 居家照護環境
  • 研究機構

第10章 全球體外診斷（IVD）市場：依地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東、非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第11章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司概況

  • Roche Diagnostics
  • Siemens Healthineers
  • Abbott Laboratories
  • Danaher Corporation（Beckman Coulter）
  • Thermo Fisher Scientific
  • Becton, Dickinson and Company（BD）
  • bioMerieux SA
  • Sysmex Corporation
  • Johnson & Johnson（Ortho Clinical Diagnostics）
  • Bio-Rad Laboratories
  • Qiagen NV
  • Hologic, Inc.
  • Grifols
  • Illumina, Inc.
  • Agilent Technologies
Product Code: SMRC26431

According to Stratistics MRC, the Global In Vitro Diagnostics (IVD) Market is accounted for $104.1 billion in 2024 and is expected to reach $148.5 billion by 2030 growing at a CAGR of 6.1% during the forecast period. In Vitro Diagnostics (IVD) refers to medical tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections. These tests are conducted outside the body, in a controlled laboratory environment, to provide crucial information for diagnosis, treatment monitoring, and disease prevention, playing a vital role in modern healthcare and personalized medicine.

According to a report by the National Center for Biotechnology Information (NCBI), IVD testing is valuable in clinical practice, with 88% of patients using it for initial diagnosis, 77% for treatment monitoring, and 72% for follow-up. This highlights the indispensable role of IVDs in patient management and healthcare outcomes.

Market Dynamics:

Driver:

Increasing prevalence of chronic diseases

The rising prevalence of chronic diseases such as diabetes, cardiovascular diseases, and cancer is a significant driver for the In Vitro Diagnostics (IVD) market. These conditions require regular monitoring and early diagnosis, which IVD tests facilitate. As the global population ages and lifestyle-related health issues increase, the demand for accurate and efficient diagnostic tools continues to grow, thereby driving market expansion.

Restraint:

High cost of diagnostic platforms

The high cost of advanced diagnostic platforms poses a significant restraint to the IVD market. These platforms often require substantial investment in terms of initial setup, maintenance, and skilled personnel. Smaller healthcare facilities and developing regions may find it challenging to afford these technologies, limiting their adoption and slowing market growth. Additionally, the cost factor can deter frequent upgrades and integration of new technologies.

Opportunity:

Growth in emerging markets

Emerging markets present substantial growth opportunities for the IVD market. Regions such as Asia-Pacific, Latin America, and parts of Africa are experiencing rapid economic development, improved healthcare infrastructure, and increased healthcare spending. These factors, combined with a growing awareness of early disease detection and preventive healthcare, create a fertile ground for the expansion of IVD products and services. Companies investing in these regions can tap into a large, underserved patient population.

Threat:

Stringent regulatory framework

The stringent regulatory framework governing the approval and commercialization of IVD products is a significant threat to market growth. Regulatory bodies like the FDA and EMA impose rigorous standards to ensure the safety and efficacy of diagnostic tests. While these regulations protect patient safety, they also lead to lengthy approval processes and increased costs for manufacturers. Non-compliance can result in product recalls, legal issues, and loss of market credibility.

Covid-19 Impact:

The COVID-19 pandemic significantly boosted the IVD market, with a sharp rise in demand for diagnostic tests such as PCR, NGS, and serology-based rapid tests. The pandemic accelerated the adoption of point-of-care testing and remote diagnostics, highlighting the importance of rapid and accurate diagnostic solutions. This surge in demand led to increased investments in IVD technologies and infrastructure, setting a precedent for future growth.

The reagents & kits segment is expected to be the largest during the forecast period

The reagents and kits segment is anticipated to dominate the IVD market due to their essential role in diagnostic testing. Reagents are critical components used in various IVD tests to detect and measure specific analytes in patient samples. The continuous need for these consumables in routine diagnostic procedures, coupled with advancements in reagent formulations and the introduction of new test kits, drives the segment's growth.

The immunoassays segment is expected to have the highest CAGR during the forecast period

The immunoassays segment is projected to experience the highest CAGR due to its widespread application in detecting infectious diseases, cancer biomarkers, and hormone levels. Immunoassays offer high sensitivity and specificity, making them indispensable in clinical diagnostics. Technological advancements, such as the development of automated immunoassay systems and multiplex assays, further enhance their efficiency and adoption, contributing to rapid market growth.

Region with largest share:

North America is positioned to dominate the IVD market due to its advanced healthcare infrastructure, high healthcare expenditure, and the presence of major IVD companies. The region's focus on early disease detection, personalized medicine, and the adoption of advanced diagnostic technologies drives market growth. Additionally, supportive government policies and a high prevalence of chronic diseases contribute to North America's leading market share.

Region with highest CAGR:

The Asia Pacific region anticipates rapid growth in the IVD market, driven by increasing healthcare investments, improving healthcare infrastructure, and a growing awareness of preventive healthcare. The rising prevalence of chronic and infectious diseases, coupled with economic development and expanding middle-class populations, fuels the demand for advanced diagnostic solutions. Government initiatives to enhance healthcare access and affordability further support the region's high CAGR.

Key players in the market

Some of the key players in In Vitro Diagnostics (IVD) market include Roche Diagnostics, Siemens Healthineers, Abbott Laboratories, Danaher Corporation (Beckman Coulter), Thermo Fisher Scientific, Becton, Dickinson and Company (BD), bioMerieux SA, Sysmex Corporation, Johnson & Johnson (Ortho Clinical Diagnostics), Bio-Rad Laboratories, Qiagen N.V., Hologic, Inc., Grifols, Illumina, Inc., and Agilent Technologies.

Key Developments:

In December 2023, Thermo Fisher Scientific Inc., the world leader in serving science, announced the launch of the Thermo Scientific(TM) KingFisher(TM) Apex(TM) Dx, an automated nucleic acid purification instrument, and Applied Biosystems(TM) MagMAX(TM) Dx Viral/Pathogen NA Isolation Kit for the isolation and purification of viral and bacterial pathogens from respiratory biological specimens. Together these products provide laboratories with an in vitro diagnostic (IVD) and in vitro diagnostic regulation (IVD-R) approved automated sample preparation solutions for increased confidence in downstream results.

In November 2023, Roche announced the launch of the LightCycler(R) PRO System based on the proven gold standard technology of the LightCycler(R) Systems that came before it. This new system raises the bar for performance and usability while bridging the gap between translational research and in vitro diagnostics. The LightCycler PRO System further complements Roche's molecular PCR testing portfolio, which includes solutions for a variety of healthcare professionals - from those performing research, to those testing patients for cancer, infectious diseases, and other public health challenges.

In June 2023, Hologic announced FDA 510(k) clearance of its Panther Fusion SARS-CoV-2/Flu A/B/RSV assay. The news came months after the FDA granted an emergency use authorization for a COVID/flu/RSV test from BD.

Products Covered:

  • Instruments
  • Reagents & Kits
  • Software

Specimens Covered:

  • Blood
  • Urine
  • Stool
  • Saliva
  • Tissue Biopsies
  • Other Specimens

Technologies Covered:

  • Immunoassays
  • Molecular Diagnostics
  • Clinical Chemistry
  • Hematology
  • Microbiology
  • Coagulation & Hemostasis
  • Other Technologies

Applications Covered:

  • Infectious Diseases
  • Oncology
  • Endocrinology
  • Cardiology
  • Blood Screening
  • Genetic Testing
  • Autoimmune Diseases
  • Allergy Diagnostics
  • Drug Monitoring & Testing
  • Coagulation Testing
  • Other Applications

End Users Covered:

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Point-of-Care Testing Sites
  • Homecare Settings
  • Research Institutions

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global In Vitro Diagnostics (IVD) Market, By Product

  • 5.1 Introduction
  • 5.2 Instruments
    • 5.2.1 Analyzers
    • 5.2.2 Point-of-care (POC) devices
    • 5.2.3 Microscopes
    • 5.2.4 Other Instruments
  • 5.3 Reagents & Kits
    • 5.3.1 Molecular Diagnostics Kits
    • 5.3.2 Clinical Chemistry Assays
    • 5.3.3 Hematology Assays
    • 5.3.4 Microbiology Assays
    • 5.3.5 Other Reagents & Kits
  • 5.4 Software
    • 5.4.1 Data Analysis Software
    • 5.4.2 Laboratory Information Management Systems (LIMS)
    • 5.4.3 Remote Diagnostics Software

6 Global In Vitro Diagnostics (IVD) Market, By Specimen

  • 6.1 Introduction
  • 6.2 Blood
  • 6.3 Urine
  • 6.4 Stool
  • 6.5 Saliva
  • 6.6 Tissue Biopsies
  • 6.7 Other Specimens

7 Global In Vitro Diagnostics (IVD) Market, By Technology

  • 7.1 Introduction
  • 7.2 Immunoassays
    • 7.2.1 Enzyme-Linked Immunosorbent Assay (ELISA)
    • 7.2.2 Chemiluminescence Immunoassays (CLIA)
    • 7.2.3 Radioimmunoassay (RIA)
  • 7.3 Molecular Diagnostics
    • 7.3.1 Polymerase Chain Reaction (PCR)
    • 7.3.2 Isothermal Nucleic Acid Amplification Technology (INAAT)
    • 7.3.3 Microarrays
    • 7.3.4 Next-Generation Sequencing (NGS)
  • 7.4 Clinical Chemistry
  • 7.5 Hematology
  • 7.6 Microbiology
  • 7.7 Coagulation & Hemostasis
  • 7.8 Other Technologies

8 Global In Vitro Diagnostics (IVD) Market, By Application

  • 8.1 Introduction
  • 8.2 Infectious Diseases
    • 8.2.1 HIV/AIDS Testing
    • 8.2.2 Hepatitis Testing
    • 8.2.3 Bacterial & Viral Infections
  • 8.3 Oncology
    • 8.3.1 Cancer Screening & Diagnosis
    • 8.3.2 Monitoring Treatment Response
  • 8.4 Endocrinology
    • 8.4.1 Diabetes Testing
    • 8.4.2 Thyroid Function Testing
  • 8.5 Cardiology
    • 8.5.1 Cardiac Markers Testing
    • 8.5.2 Cholesterol Testing
  • 8.6 Blood Screening
    • 8.6.1 Newborn Screening
    • 8.6.2 Prenatal Testing
  • 8.7 Genetic Testing
    • 8.7.1 Carrier Screening
    • 8.7.2 Pharmacogenomics
  • 8.8 Autoimmune Diseases
    • 8.8.1 Rheumatoid Arthritis Testing
    • 8.8.2 Celiac Disease Testing
  • 8.9 Allergy Diagnostics
    • 8.9.1 Food Allergy Testing
    • 8.9.2 Drug Allergy Testing
  • 8.10 Drug Monitoring & Testing
    • 8.10.1 Therapeutic Drug monitoring
    • 8.10.2 Anti-doping Testing
  • 8.11 Coagulation Testing
    • 8.11.1 Blood Group Typing
    • 8.11.2 Bone & Mineral Disorders
  • 8.12 Other Applications

9 Global In Vitro Diagnostics (IVD) Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals & Clinics
  • 9.3 Diagnostic Laboratories
  • 9.4 Point-of-Care Testing Sites
  • 9.5 Homecare Settings
  • 9.6 Research Institutions

10 Global In Vitro Diagnostics (IVD) Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Roche Diagnostics
  • 12.2 Siemens Healthineers
  • 12.3 Abbott Laboratories
  • 12.4 Danaher Corporation (Beckman Coulter)
  • 12.5 Thermo Fisher Scientific
  • 12.6 Becton, Dickinson and Company (BD)
  • 12.7 bioMerieux SA
  • 12.8 Sysmex Corporation
  • 12.9 Johnson & Johnson (Ortho Clinical Diagnostics)
  • 12.10 Bio-Rad Laboratories
  • 12.11 Qiagen N.V.
  • 12.12 Hologic, Inc.
  • 12.13 Grifols
  • 12.14 Illumina, Inc.
  • 12.15 Agilent Technologies

List of Tables

  • Table 1 Global In Vitro Diagnostics (IVD) Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global In Vitro Diagnostics (IVD) Market Outlook, By Product (2022-2030) ($MN)
  • Table 3 Global In Vitro Diagnostics (IVD) Market Outlook, By Instruments (2022-2030) ($MN)
  • Table 4 Global In Vitro Diagnostics (IVD) Market Outlook, By Analyzers (2022-2030) ($MN)
  • Table 5 Global In Vitro Diagnostics (IVD) Market Outlook, By Point-of-care (POC) devices (2022-2030) ($MN)
  • Table 6 Global In Vitro Diagnostics (IVD) Market Outlook, By Microscopes (2022-2030) ($MN)
  • Table 7 Global In Vitro Diagnostics (IVD) Market Outlook, By Other Instruments (2022-2030) ($MN)
  • Table 8 Global In Vitro Diagnostics (IVD) Market Outlook, By Reagents & Kits (2022-2030) ($MN)
  • Table 9 Global In Vitro Diagnostics (IVD) Market Outlook, By Molecular Diagnostics Kits (2022-2030) ($MN)
  • Table 10 Global In Vitro Diagnostics (IVD) Market Outlook, By Clinical Chemistry Assays (2022-2030) ($MN)
  • Table 11 Global In Vitro Diagnostics (IVD) Market Outlook, By Hematology Assays (2022-2030) ($MN)
  • Table 12 Global In Vitro Diagnostics (IVD) Market Outlook, By Microbiology Assays (2022-2030) ($MN)
  • Table 13 Global In Vitro Diagnostics (IVD) Market Outlook, By Other Reagents & Kits (2022-2030) ($MN)
  • Table 14 Global In Vitro Diagnostics (IVD) Market Outlook, By Software (2022-2030) ($MN)
  • Table 15 Global In Vitro Diagnostics (IVD) Market Outlook, By Data Analysis Software (2022-2030) ($MN)
  • Table 16 Global In Vitro Diagnostics (IVD) Market Outlook, By Laboratory Information Management Systems (LIMS) (2022-2030) ($MN)
  • Table 17 Global In Vitro Diagnostics (IVD) Market Outlook, By Remote Diagnostics Software (2022-2030) ($MN)
  • Table 18 Global In Vitro Diagnostics (IVD) Market Outlook, By Specimen (2022-2030) ($MN)
  • Table 19 Global In Vitro Diagnostics (IVD) Market Outlook, By Blood (2022-2030) ($MN)
  • Table 20 Global In Vitro Diagnostics (IVD) Market Outlook, By Urine (2022-2030) ($MN)
  • Table 21 Global In Vitro Diagnostics (IVD) Market Outlook, By Stool (2022-2030) ($MN)
  • Table 22 Global In Vitro Diagnostics (IVD) Market Outlook, By Saliva (2022-2030) ($MN)
  • Table 23 Global In Vitro Diagnostics (IVD) Market Outlook, By Tissue Biopsies (2022-2030) ($MN)
  • Table 24 Global In Vitro Diagnostics (IVD) Market Outlook, By Other Specimens (2022-2030) ($MN)
  • Table 25 Global In Vitro Diagnostics (IVD) Market Outlook, By Technology (2022-2030) ($MN)
  • Table 26 Global In Vitro Diagnostics (IVD) Market Outlook, By Immunoassays (2022-2030) ($MN)
  • Table 27 Global In Vitro Diagnostics (IVD) Market Outlook, By Enzyme-Linked Immunosorbent Assay (ELISA) (2022-2030) ($MN)
  • Table 28 Global In Vitro Diagnostics (IVD) Market Outlook, By Chemiluminescence Immunoassays (CLIA) (2022-2030) ($MN)
  • Table 29 Global In Vitro Diagnostics (IVD) Market Outlook, By Radioimmunoassay (RIA) (2022-2030) ($MN)
  • Table 30 Global In Vitro Diagnostics (IVD) Market Outlook, By Molecular Diagnostics (2022-2030) ($MN)
  • Table 31 Global In Vitro Diagnostics (IVD) Market Outlook, By Polymerase Chain Reaction (PCR) (2022-2030) ($MN)
  • Table 32 Global In Vitro Diagnostics (IVD) Market Outlook, By Isothermal Nucleic Acid Amplification Technology (INAAT) (2022-2030) ($MN)
  • Table 33 Global In Vitro Diagnostics (IVD) Market Outlook, By Microarrays (2022-2030) ($MN)
  • Table 34 Global In Vitro Diagnostics (IVD) Market Outlook, By Next-Generation Sequencing (NGS) (2022-2030) ($MN)
  • Table 35 Global In Vitro Diagnostics (IVD) Market Outlook, By Clinical Chemistry (2022-2030) ($MN)
  • Table 36 Global In Vitro Diagnostics (IVD) Market Outlook, By Hematology (2022-2030) ($MN)
  • Table 37 Global In Vitro Diagnostics (IVD) Market Outlook, By Microbiology (2022-2030) ($MN)
  • Table 38 Global In Vitro Diagnostics (IVD) Market Outlook, By Coagulation & Hemostasis (2022-2030) ($MN)
  • Table 39 Global In Vitro Diagnostics (IVD) Market Outlook, By Other Technologies (2022-2030) ($MN)
  • Table 40 Global In Vitro Diagnostics (IVD) Market Outlook, By Application (2022-2030) ($MN)
  • Table 41 Global In Vitro Diagnostics (IVD) Market Outlook, By Infectious Diseases (2022-2030) ($MN)
  • Table 42 Global In Vitro Diagnostics (IVD) Market Outlook, By HIV/AIDS Testing (2022-2030) ($MN)
  • Table 43 Global In Vitro Diagnostics (IVD) Market Outlook, By Hepatitis Testing (2022-2030) ($MN)
  • Table 44 Global In Vitro Diagnostics (IVD) Market Outlook, By Bacterial & Viral Infections (2022-2030) ($MN)
  • Table 45 Global In Vitro Diagnostics (IVD) Market Outlook, By Oncology (2022-2030) ($MN)
  • Table 46 Global In Vitro Diagnostics (IVD) Market Outlook, By Cancer Screening & Diagnosis (2022-2030) ($MN)
  • Table 47 Global In Vitro Diagnostics (IVD) Market Outlook, By Monitoring Treatment Response (2022-2030) ($MN)
  • Table 48 Global In Vitro Diagnostics (IVD) Market Outlook, By Endocrinology (2022-2030) ($MN)
  • Table 49 Global In Vitro Diagnostics (IVD) Market Outlook, By Diabetes Testing (2022-2030) ($MN)
  • Table 50 Global In Vitro Diagnostics (IVD) Market Outlook, By Thyroid Function Testing (2022-2030) ($MN)
  • Table 51 Global In Vitro Diagnostics (IVD) Market Outlook, By Cardiology (2022-2030) ($MN)
  • Table 52 Global In Vitro Diagnostics (IVD) Market Outlook, By Cardiac Markers Testing (2022-2030) ($MN)
  • Table 53 Global In Vitro Diagnostics (IVD) Market Outlook, By Cholesterol Testing (2022-2030) ($MN)
  • Table 54 Global In Vitro Diagnostics (IVD) Market Outlook, By Blood Screening (2022-2030) ($MN)
  • Table 55 Global In Vitro Diagnostics (IVD) Market Outlook, By Newborn Screening (2022-2030) ($MN)
  • Table 56 Global In Vitro Diagnostics (IVD) Market Outlook, By Prenatal Testing (2022-2030) ($MN)
  • Table 57 Global In Vitro Diagnostics (IVD) Market Outlook, By Genetic Testing (2022-2030) ($MN)
  • Table 58 Global In Vitro Diagnostics (IVD) Market Outlook, By Carrier Screening (2022-2030) ($MN)
  • Table 59 Global In Vitro Diagnostics (IVD) Market Outlook, By Pharmacogenomics (2022-2030) ($MN)
  • Table 60 Global In Vitro Diagnostics (IVD) Market Outlook, By Autoimmune Diseases (2022-2030) ($MN)
  • Table 61 Global In Vitro Diagnostics (IVD) Market Outlook, By Rheumatoid Arthritis Testing (2022-2030) ($MN)
  • Table 62 Global In Vitro Diagnostics (IVD) Market Outlook, By Celiac Disease Testing (2022-2030) ($MN)
  • Table 63 Global In Vitro Diagnostics (IVD) Market Outlook, By Allergy Diagnostics (2022-2030) ($MN)
  • Table 64 Global In Vitro Diagnostics (IVD) Market Outlook, By Food Allergy Testing (2022-2030) ($MN)
  • Table 65 Global In Vitro Diagnostics (IVD) Market Outlook, By Drug Allergy Testing (2022-2030) ($MN)
  • Table 66 Global In Vitro Diagnostics (IVD) Market Outlook, By Drug Monitoring & Testing (2022-2030) ($MN)
  • Table 67 Global In Vitro Diagnostics (IVD) Market Outlook, By Therapeutic Drug monitoring (2022-2030) ($MN)
  • Table 68 Global In Vitro Diagnostics (IVD) Market Outlook, By Anti-doping Testing (2022-2030) ($MN)
  • Table 69 Global In Vitro Diagnostics (IVD) Market Outlook, By Coagulation Testing (2022-2030) ($MN)
  • Table 70 Global In Vitro Diagnostics (IVD) Market Outlook, By Blood Group Typing (2022-2030) ($MN)
  • Table 71 Global In Vitro Diagnostics (IVD) Market Outlook, By Bone & Mineral Disorders (2022-2030) ($MN)
  • Table 72 Global In Vitro Diagnostics (IVD) Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 73 Global In Vitro Diagnostics (IVD) Market Outlook, By End User (2022-2030) ($MN)
  • Table 74 Global In Vitro Diagnostics (IVD) Market Outlook, By Hospitals & Clinics (2022-2030) ($MN)
  • Table 75 Global In Vitro Diagnostics (IVD) Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
  • Table 76 Global In Vitro Diagnostics (IVD) Market Outlook, By Point-of-Care Testing Sites (2022-2030) ($MN)
  • Table 77 Global In Vitro Diagnostics (IVD) Market Outlook, By Homecare Settings (2022-2030) ($MN)
  • Table 78 Global In Vitro Diagnostics (IVD) Market Outlook, By Research Institutions (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.